STOCK TITAN

[8-K] Leggett & Platt, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Select Medical Holdings Corp. (SEM) Form 4: Chief Information Officer Brian R. Rusignuolo reported the grant of 75,000 shares of common stock on 29-Jul-2025. The award is restricted stock that will vest in full on 29-Jul-2028, subject to customary exceptions. No cash was paid (reported price $0), indicating an equity-based compensation grant rather than an open-market purchase.

Following the transaction, Rusignuolo’s direct beneficial ownership stands at 376,050 SEM shares. No derivative securities were involved and there were no dispositions.

  • Form filed by one reporting person; no Rule 10b5-1 indication.
  • Transaction code “A” denotes an award rather than market activity.
  • The grant aligns executive interests with shareholders but represents a small fraction of SEM’s outstanding shares (exact float not disclosed in the filing).

Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha comunicato la concessione di 75.000 azioni ordinarie il 29-lug-2025. Il premio consiste in azioni vincolate che matureranno completamente il 29-lug-2028, salvo eccezioni consuete. Non è stato versato denaro (prezzo riportato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.

Dopo la transazione, la proprietà diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti strumenti derivati né sono state effettuate cessioni.

  • Modulo presentato da un unico soggetto segnalante; nessuna indicazione di Regola 10b5-1.
  • Il codice della transazione “A” indica un premio e non un’attività di mercato.
  • La concessione allinea gli interessi del dirigente con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantità esatta non è stata divulgata nel modulo).

Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Información, Brian R. Rusignuolo, reportó la concesión de 75,000 acciones ordinarias el 29-jul-2025. La asignación corresponde a acciones restringidas que se liberarán en su totalidad el 29-jul-2028, sujeto a excepciones habituales. No se pagó dinero en efectivo (precio reportado $0), lo que indica una compensación basada en acciones en lugar de una compra en el mercado abierto.

Después de la transacción, la propiedad directa beneficiosa de Rusignuolo es de 376,050 acciones SEM. No se involucraron valores derivados ni hubo disposiciones.

  • Formulario presentado por una sola persona reportante; sin indicación de la Regla 10b5-1.
  • El código de transacción “A” denota una asignación y no actividad de mercado.
  • La concesión alinea los intereses del ejecutivo con los de los accionistas, pero representa una pequeña fracción de las acciones en circulación de SEM (el número exacto no se reveló en la presentación).

Select Medical Holdings Corp. (SEM) 양식 4: 최고정보책임자 Brian R. Rusignuolo가 2025년 7월 29일에 보통주 75,000주 부여를 보고했습니다. 이 보상은 제한 주식으로 2028년 7월 29일에 전액 베스팅되며, 일반적인 예외가 적용됩니다. 현금 지급은 없었으며(보고된 가격 $0), 이는 공개 시장 구매가 아닌 주식 기반 보상임을 나타냅니다.

거래 후 Rusignuolo의 직접적 실질 소유 주식 수는 376,050 SEM 주식입니다. 파생 증권은 포함되지 않았으며 처분도 없었습니다.

  • 한 명의 신고자가 제출한 양식이며, 10b5-1 규정 표시 없음.
  • 거래 코드 “A”는 시장 활동이 아닌 보상을 의미합니다.
  • 이 부여는 임원과 주주의 이해관계를 일치시키지만 SEM의 유통 주식 중 매우 작은 비중을 차지합니다(정확한 유통 주식 수는 제출서류에 공개되지 않음).

Select Medical Holdings Corp. (SEM) Formulaire 4 : Le directeur des systèmes d'information Brian R. Rusignuolo a déclaré l'octroi de 75 000 actions ordinaires le 29-juil-2025. La récompense consiste en des actions restreintes qui seront entièrement acquises le 29-juil-2028, sous réserve des exceptions habituelles. Aucun paiement en espèces n'a été effectué (prix déclaré 0 $), indiquant une rémunération en actions plutôt qu'un achat sur le marché libre.

Après la transaction, la propriété directe bénéficiaire de Rusignuolo s'élève à 376 050 actions SEM. Aucun titre dérivé n'a été impliqué et aucune cession n'a eu lieu.

  • Formulaire déposé par une seule personne déclarant ; pas d'indication de la règle 10b5-1.
  • Le code de transaction « A » désigne une attribution et non une activité de marché.
  • L'octroi aligne les intérêts des dirigeants avec ceux des actionnaires, mais représente une petite fraction des actions en circulation de SEM (le flottant exact n'a pas été divulgué dans le dépôt).

Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gewährung von 75.000 Stammaktien am 29. Juli 2025. Die Zuwendung besteht aus eingeschränkten Aktien, die am 29. Juli 2028 vollständig unverfallbar werden, vorbehaltlich üblicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Vergütung und keinen Kauf am offenen Markt hinweist.

Nach der Transaktion hält Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

  • Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
  • Der Transaktionscode „A“ steht für eine Zuwendung und nicht für Marktaktivität.
  • Die Gewährung richtet die Interessen des Managements an denen der Aktionäre aus, stellt jedoch nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (die genaue Streuung wurde in der Meldung nicht offenbart).
Positive
  • Executive ownership increases by 75,000 shares, enhancing alignment between CIO and shareholders.
Negative
  • None.

Insights

TL;DR: Executive awarded 75k restricted shares; modest, alignment-oriented, limited dilution—neutral market impact.

The filing documents a time-vested equity grant to the CIO. Such awards are typical for retention and incentive purposes. The additional 75k shares lift total insider holdings to 376k, signaling continued commitment but not an outright open-market buy. Because the shares come from equity incentive plans, dilution impact is de minimis relative to SEM’s overall share count. No pricing, derivative activity, or concurrent sales appear, so the transaction neither conveys strong bullish nor bearish insider sentiment. I classify the market impact as neutral.

Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha comunicato la concessione di 75.000 azioni ordinarie il 29-lug-2025. Il premio consiste in azioni vincolate che matureranno completamente il 29-lug-2028, salvo eccezioni consuete. Non è stato versato denaro (prezzo riportato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.

Dopo la transazione, la proprietà diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti strumenti derivati né sono state effettuate cessioni.

  • Modulo presentato da un unico soggetto segnalante; nessuna indicazione di Regola 10b5-1.
  • Il codice della transazione “A” indica un premio e non un’attività di mercato.
  • La concessione allinea gli interessi del dirigente con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantità esatta non è stata divulgata nel modulo).

Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Información, Brian R. Rusignuolo, reportó la concesión de 75,000 acciones ordinarias el 29-jul-2025. La asignación corresponde a acciones restringidas que se liberarán en su totalidad el 29-jul-2028, sujeto a excepciones habituales. No se pagó dinero en efectivo (precio reportado $0), lo que indica una compensación basada en acciones en lugar de una compra en el mercado abierto.

Después de la transacción, la propiedad directa beneficiosa de Rusignuolo es de 376,050 acciones SEM. No se involucraron valores derivados ni hubo disposiciones.

  • Formulario presentado por una sola persona reportante; sin indicación de la Regla 10b5-1.
  • El código de transacción “A” denota una asignación y no actividad de mercado.
  • La concesión alinea los intereses del ejecutivo con los de los accionistas, pero representa una pequeña fracción de las acciones en circulación de SEM (el número exacto no se reveló en la presentación).

Select Medical Holdings Corp. (SEM) 양식 4: 최고정보책임자 Brian R. Rusignuolo가 2025년 7월 29일에 보통주 75,000주 부여를 보고했습니다. 이 보상은 제한 주식으로 2028년 7월 29일에 전액 베스팅되며, 일반적인 예외가 적용됩니다. 현금 지급은 없었으며(보고된 가격 $0), 이는 공개 시장 구매가 아닌 주식 기반 보상임을 나타냅니다.

거래 후 Rusignuolo의 직접적 실질 소유 주식 수는 376,050 SEM 주식입니다. 파생 증권은 포함되지 않았으며 처분도 없었습니다.

  • 한 명의 신고자가 제출한 양식이며, 10b5-1 규정 표시 없음.
  • 거래 코드 “A”는 시장 활동이 아닌 보상을 의미합니다.
  • 이 부여는 임원과 주주의 이해관계를 일치시키지만 SEM의 유통 주식 중 매우 작은 비중을 차지합니다(정확한 유통 주식 수는 제출서류에 공개되지 않음).

Select Medical Holdings Corp. (SEM) Formulaire 4 : Le directeur des systèmes d'information Brian R. Rusignuolo a déclaré l'octroi de 75 000 actions ordinaires le 29-juil-2025. La récompense consiste en des actions restreintes qui seront entièrement acquises le 29-juil-2028, sous réserve des exceptions habituelles. Aucun paiement en espèces n'a été effectué (prix déclaré 0 $), indiquant une rémunération en actions plutôt qu'un achat sur le marché libre.

Après la transaction, la propriété directe bénéficiaire de Rusignuolo s'élève à 376 050 actions SEM. Aucun titre dérivé n'a été impliqué et aucune cession n'a eu lieu.

  • Formulaire déposé par une seule personne déclarant ; pas d'indication de la règle 10b5-1.
  • Le code de transaction « A » désigne une attribution et non une activité de marché.
  • L'octroi aligne les intérêts des dirigeants avec ceux des actionnaires, mais représente une petite fraction des actions en circulation de SEM (le flottant exact n'a pas été divulgué dans le dépôt).

Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gewährung von 75.000 Stammaktien am 29. Juli 2025. Die Zuwendung besteht aus eingeschränkten Aktien, die am 29. Juli 2028 vollständig unverfallbar werden, vorbehaltlich üblicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Vergütung und keinen Kauf am offenen Markt hinweist.

Nach der Transaktion hält Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

  • Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
  • Der Transaktionscode „A“ steht für eine Zuwendung und nicht für Marktaktivität.
  • Die Gewährung richtet die Interessen des Managements an denen der Aktionäre aus, stellt jedoch nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (die genaue Streuung wurde in der Meldung nicht offenbart).
LEGGETT & PLATT INC false 0000058492 0000058492 2025-07-31 2025-07-31
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 31, 2025

 

 

LEGGETT & PLATT, INCORPORATED

(Exact name of registrant as specified in its charter)

 

 

 

Missouri   001-07845   44-0324630

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1 Leggett Road  
Carthage, MO   64836
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code 417-358-8131

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $.01 par value   LEG   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02

Results of Operations and Financial Condition.

On July 31, 2025, Leggett & Platt, Incorporated (the “Company”) issued a press release announcing its financial results for the second quarter ending June 30, 2025 and related matters. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

This information is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be incorporated by reference into any document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

On August 1, 2025, the Company will hold an investor conference call to discuss its second quarter results, annual earnings guidance, market conditions, company initiatives, and related matters.

The press release contains the Company’s (i) Net Debt/Adjusted EBITDA (trailing twelve months) ratio; (ii) Adjusted EPS; (iii) Adjusted EBIT; (iv) Adjusted EBIT Margin; (v) EBITDA; (vi) EBITDA Margin; (vii) Adjusted EBITDA; (viii) Adjusted EBITDA Margin; (ix) Adjusted EBITDA (trailing twelve months); and (x) change in Organic Sales.

The press release also contains Segments’ (i) Adjusted EBIT; (ii) Adjusted EBIT Margin; (iii) Adjusted EBITDA; (iv) Adjusted EBITDA Margin; and (v) change in Organic Sales.

Company management believes the presentation of Net Debt/Adjusted EBITDA (trailing twelve months) provides investors a useful way to assess the time it would take the Company to pay off its debt, ignoring various factors including interest and taxes. Management uses this ratio as supplemental information to assess its ability to pay off its incurred debt. Because we may not be able to use our earnings to reduce our debt on a dollar-for-dollar basis, the presentation of Net Debt/Adjusted EBITDA (trailing twelve months) may have material limitations.

Company management believes the presentation of Company Adjusted EPS, Adjusted EBIT, Adjusted EBIT Margin, EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted EBITDA (trailing twelve months), and Segment Adjusted EBIT, Adjusted EBIT Margin, Adjusted EBITDA, and Adjusted EBITDA Margin is useful to investors in that it aids investors’ understanding of underlying operational profitability. Management uses these non-GAAP measures as supplemental information to assess the Company’s operational performance.

Organic Sales is calculated as trade sales excluding sales attributable to acquisitions and divestitures consummated within the last twelve months. Company management believes the presentation of change in Organic Sales is useful to investors and is used by management as supplemental information to analyze our underlying sales performance from period to period in our legacy businesses.

The above non-GAAP measures may not be comparable to similarly titled measures used by other companies and should not be considered a substitute for, or more meaningful than, their GAAP counterparts. For non-GAAP reconciliations, please refer to pages 7 and 8 of the press release.

 

Item 7.01

Regulation FD Disclosure.

The information provided in Item 2.02, including Exhibit 99.1, is incorporated herein by reference.

 

 

2


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT INDEX

 

Exhibit
No.

  

Description

99.1*    Press Release dated July 31, 2025
104    Cover Page Interactive Data File (embedded within the inline XBRL document)

 

*

Denotes furnished herewith.

 

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LEGGETT & PLATT, INCORPORATED
Date: July 31, 2025     By:  

/s/ Jennifer J. Davis

            Jennifer J. Davis
            Executive Vice President –
            General Counsel

 

4

FAQ

How many SEM shares did the CIO acquire on 29-Jul-2025?

The Form 4 reports an award of 75,000 restricted shares.

What is Brian R. Rusignuolo’s total ownership after the grant?

He now beneficially owns 376,050 shares of Select Medical Holdings Corp.

When will the restricted stock granted to SEM’s CIO vest?

The shares are scheduled to vest in full on 29-Jul-2028.

Was the transaction an open-market purchase?

No. Transaction code "A" indicates an equity award; the price reported was $0.

Does the filing mention any derivative securities?

No derivative securities were acquired or disposed of in this Form 4.
Leggett & Platt Inc

NYSE:LEG

LEG Rankings

LEG Latest News

LEG Latest SEC Filings

LEG Stock Data

1.31B
131.70M
2.56%
76.83%
5.76%
Furnishings, Fixtures & Appliances
Household Furniture
Link
United States
CARTHAGE